LIFE: Lifecare announces presentation of additional clinical data from study LFS-SEN-001

Bergen, Norway, September 22, 2023: Lifecare AS (LIFE), a clinical stage medical
sensor company developing the next generation Continuous Glucose Monitor (CGM)
announce today that additional clinical data from study LFS-SEN-001 will be
presented at the upcoming international diabetes conference hosted by the
Diabetes Technology Society.  

Lifecare CSO, Professor Dr. Dr. Med. Andreas Pfützner has received an invitation
to present the poster "Continuous Glucose Monitoring with an Osmotic-Pressure
Based Continuous Glucose Sensor: Results of the First Human Pilot Study" 
at the annual Diabetes Technology Meeting (DTM), Tuesday November 7th, 2023. 

The results from Lifecare's clinical study LFS-SEN-001 were first presented at
the American Diabetes Association Scientific Sessions (ADA) in San Diego, CA,
USA, in June 2023, as a late breaking abstract. At the upcoming DTM, additional
data will be presented.

The study data presented at the ADA included proof-of-concept in human tissue,
as well as confirmation that Lifecare's CGM system Sencell has a solid clinical
accuracy: the mean average of absolute error (MARD) value was calculated to
9,6%. 

In context, regulatory authorities expect a MARD below 10% to acknowledge CGM
for therapeutic (medical) decisions such as insulin dose adjustments. In
comparison, the MARD of glucose measurements in capillary blood (Blood Glucose
Monitoring - BGM), representing the gold standard for patient self-monitoring of
glucose, are in the range 5-10%.

The Sencell MARD confirms previous communication from Lifecare that the system
is at least as accurate as commercially available CGM systems. At the current
development stage, the sensor sensitivity and algorithm development provide
accuracy far better than expected.

******

Lifecare AS is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on
the sensor body for read-out of pressure variations. LifecareŽs sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the human
body.¬¬¬

******

For further information, please contact: 
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act.